MedTrakRx Revenue and Competitors

Location

N/A

Total Funding

Insurance

Industry

Estimated Revenue & Valuation

  • MedTrakRx's estimated annual revenue is currently $83.6M per year.(i)
  • MedTrakRx's estimated revenue per employee is $275,000

Employee Data

  • MedTrakRx has 304 Employees.(i)
  • MedTrakRx grew their employee count by 9% last year.

MedTrakRx's People

NameTitleEmail/Phone
1
ControllerReveal Email/Phone
2
Customer Service ManagerReveal Email/Phone
3
Software Developer IIReveal Email/Phone
4
PBAReveal Email/Phone
5
AccountingReveal Email/Phone
6
Pharmacy Benefit AdvisorReveal Email/Phone
7
Accounting AssistantReveal Email/Phone
8
Account ExecutiveReveal Email/Phone
9
System AdministratorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.2M1100%N/AN/A
#2
$6.2M35-31%N/AN/A
#3
$20.7M942%N/AN/A
#4
$30.6M13914%N/AN/A
#5
$402.6M1307N/AN/AN/A
#6
$23.1M10544%N/AN/A
#7
$23.5M10723%N/AN/A
#8
$52.5M2176%N/AN/A
#9
$55.2M2289%N/AN/A
#10
$2.2M176%N/AN/A
Add Company

What Is MedTrakRx?

MedTrakRx provides pharmacy benefits with reduced costs and personalized customer service to middle market self-insured employers. As a national pharmacy benefit management (PBM) company founded with the goals of managing prescription benefit costs while providing better customer service than anyone in the industry, MedTrakRx offers the flexibility to customize plan designs and clinical programs based each client's unique needs. MedTrakRx has built its reputation for excellence as the PBM of choice for hundreds of self-insured employers, brokers, third party administrators, and consultants. MedTrakRx is a member of the EnvisionRxOptions family of companies, which is a subsidiary of the Rite Aid Corporation.

keywords:N/A

N/A

Total Funding

304

Number of Employees

$83.6M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A3147%N/A
#2
$39.4M315N/AN/A
#3
$39.4M31532%N/A
#4
$88.3M3215%N/A
#5
$64.4M32217%N/A